The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Frontline, fixed-duration venetoclax/obinutuzumab: PFS and MRD data from CLL14
Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data on the CLL14 trial (NCT02242942) that were presented at the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. This was a trial of fixed-duration venetoclax and obinutuzumab, and the results presented demonstrated the impact of this treatment on PFS and MRD status in previously untreated chronic lympocytic leukemia (CLL).
